PTC Therapeutics
Trending Articles
Related Content
Pharmaceutical
RG7916 granted orphan drug designation in the US for the treatment of spinal muscular atrophy
PTC Therapeutics, Inc. today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RG7916 for the treatment of patients with Spinal Muscular Atrophy (SMA).
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.